Which are the causes of Sjögren-Larsson Syndrome?

Sjögren-Larsson Syndrome is a rare, inherited metabolic disorder caused by mutations in the ALDH3A2 gene, which leads to a deficiency in the fatty aldehyde dehydrogenase enzyme. This enzyme deficiency prevents the body from properly breaking down specific fatty substances, resulting in their toxic accumulation in the skin, brain, and retina.

What is the genetic cause of Sjögren-Larsson Syndrome?

Sjögren-Larsson Syndrome is strictly a genetic condition caused by mutations in the ALDH3A2 gene located on chromosome 17p11.2. This gene provides instructions for creating the fatty aldehyde dehydrogenase enzyme. When this enzyme is inactive or missing, fatty aldehydes cannot be converted into fatty acids, causing them to build up in cells and interfere with normal cellular function. Because it is an autosomal recessive condition, a child must inherit one mutated gene copy from each parent to develop Sjögren-Larsson Syndrome.

Are there environmental triggers for Sjögren-Larsson Syndrome?

There are no environmental triggers, infections, or lifestyle factors that cause Sjögren-Larsson Syndrome. Unlike autoimmune diseases where external factors might trigger an immune response, this is a purely metabolic error present at birth. While the internal environment of the body is affected by the accumulation of toxic lipids, external factors like diet or climate do not initiate the underlying genetic malfunction.

How does the enzyme deficiency affect the body?

The deficiency of fatty aldehyde dehydrogenase disrupts the lipid metabolism, which is essential for maintaining the protective barrier of the skin and the health of the nervous system. The primary consequences include:

• Ichthyosis: A severe, persistent scaling of the skin due to impaired lipid barrier formation.


• Neurological impairment: Developmental delays and spasticity caused by lipid accumulation in the brain and spinal cord.


• Ocular involvement: The development of glistening white retinal spots, known as crystalline maculopathy, which can impact vision.

What is the current research into Sjögren-Larsson Syndrome?

Researchers are currently investigating potential therapeutic pathways to bypass the metabolic block in Sjögren-Larsson Syndrome. Studies are looking into enzyme replacement therapies and pharmacological agents that might help stabilize the remaining enzyme activity or manage the toxic buildup of fatty aldehydes. Because Sjögren-Larsson Syndrome is rare, international collaboration is critical for understanding the long-term clinical progression of the 14 community members currently sharing their experiences on DiseaseMaps.org.

Next steps

• Consult with a clinical geneticist to confirm a diagnosis via ALDH3A2 molecular genetic testing.


• Seek a referral to a metabolic specialist or a neurologist familiar with rare lipid storage disorders.


• Connect with the Sjögren-Larsson Syndrome community at DiseaseMaps.org to exchange management strategies and support.

Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Sjögren-Larsson Syndrome.


• Online Mendelian Inheritance in Man (OMIM): Entry #270200.


• Orphanet: Rare Disease Database (ORPHA:3197).